H.C. Wainwright has recently initiated Verve Therapeutics Inc (VERV) stock to Buy rating, as announced on April 8, 2024, according to Finviz. Earlier, on April 13, 2023, Canaccord Genuity had initiated the stock to Buy, setting a price target of $29. Cantor Fitzgerald also initiated Neutral rating with a price target of $21. Additionally, Goldman initiated Sell rating on December 15, 2022, with a target price of $13. Credit Suisse analysts, in their report published on October 6, 2022, also initiated Neutral rating and set a price target of $48 for Verve Therapeutics Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Verve Therapeutics Inc (VERV) Stock Trading Recap
On Monday, Verve Therapeutics Inc (VERV) stock saw a decline, ending the day at $4.84 which represents a decrease of $-0.14 or -2.81% from the prior close of $4.98. The stock opened at $4.89 and touched a low of $4.79 during the day, reaching a high of $5.09. The volume of shares traded was 0.82 million falling short of the average volume of 1.43 million.
VERV Stock Performance and Moving Averages
In recent trading, Verve Therapeutics Inc (VERV) stock price has shown some volatility, fluctuating -3.59% over the last five trades and -21.04% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by -62.16%, and it has plunged by -2.81% in the previous three months. Currently, VERV is trading at -11.86%, -15.40%, and -44.80% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, VERV, a Healthcare sector stock, is trading -75.94% below its 52-week high but remains 12.43% above its 52-week low. The Average True Range (ATR) (14 days) of 0.39 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Verve Therapeutics Inc’s Profitability and Valuation Ratios
Verve Therapeutics Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of -1075.00% and a profit margin of -933.02%, with a gross margin of -62.16%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Verve Therapeutics Inc’s market capitalization stands at $409.56 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. Additionally, the Price-to-Sales Ratio is 19.83, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 0.75, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 26.18% of Verve Therapeutics Inc (VERV)’s shares, while financial institutions hold 68.97%.
